［1］MILLER KD,NOGUEIRA L,MARIOTTO AB,et al.Cancer treatment and survivorship statistics,2019［J］.CA Cancer J Clin,2019,69(5):363-385.
［2］FARGE D,FRERE C,CONNORS JM,et al.2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer［J］.Lancet Oncol,2019,20(10):e566-e581.
［3］马军,秦叔逵,吴一龙，等.肿瘤相关静脉血栓栓塞症预防与治疗指南（2019版）［J］.中国肿瘤临床,2019,46(13):653-660.
MA J,QIN SK,WU YL,et al.Guidelines for the prevention and treatment of tumor-associated venous thromboembolism（2019）［J］.Chin J Clin Oncol,2019,46(13):653-660.
［4］LITT HK,PARKS AL,VELAZQUEZ AI.Blood clots,or thrombosis,in patients with cancer［J］.JAMA Oncol,2023,9(6):876.
［5］CAMPELLO E,ILICH A,SIMIONI P,et al.The relationship between pancreatic cancer and hypercoagulability:a comprehensive review on epidemiological and biological issues［J］.Br J Cancer,2019,121(5):359-371.
［6］PRADES J,ARNOLD D,BRUNNER T,et al.Bratislava Statement:consensus recommendations for improving pancreatic cancer care［J］.ESMO Open,2020,5(6):e001051.
［7］VAN DEN BERG YW,OSANTO S,REITSMA PH,et al.The relationship between tissue factor and cancer progression:insights from bench and bedside［J］.Blood,2012,119(4):924-932.
［8］KHORANA AA,AHRENDT SA,RYAN CK,et al.Tissue factor expression,angiogenesis,and thrombosis in pancreatic cancer［J］.Clin Cancer Res,2007,13(10):2870-2875.
［9］SAWAI H,LIU J,REBER HA,et al.Activation of peroxisome proliferator-activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system［J］.Mol Cancer Res,2006,4(3):159-167.
［10］FALANGA A,MARCHETTI M,RUSSO L.The mechanisms of cancer-associated thrombosis［J］.Thromb Res,2015,135,S8-S11.
［11］FALANGA A,SCHIEPPATI F,RUSSO L.Pathophysiology mechanisms of thrombosis in cancer patients［J］.Cancer Treat Res,2019,179:11-36.
［12］BUIJS JT,VERSTEEG HH.Genes and proteins associated with the risk for cancer-associated thrombosis［J］.Thromb Res,2020,191:S43-S49.
［13］MUSE O,PATELL R,PETERS CG,et al.The unfolded protein response links ER stress to cancer-associated thrombosis［J］.JCI Insight,2023,31,8(19):e170148.
［14］ADES S,KUMAR S,ALAM M,et al.Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer［J］.J Thromb Haemost,2015,13(6):998-1003.
［15］ANSARI D,ANSARI D,ANDERSSON R,et al.Pancreatic cancer and thromboembolic disease,150 years after trousseau［J］.Hepatobiliary Surg Nutr,2015,4(5):325-335.
［16］李廷廷,战翠萍,崔久嵬.癌症相关性血栓形成的病理机制进展［J］.中国实验诊断学,2019,23(05):932-935.
LI TT,ZHAN CP,CUI JW.Progress of pathologic mechanism of cancer - associated thrombosis［J］.Chinese Journal of Laboratory Diagnosis,2019,23(05):932-935.
［17］ILICH A,BOKAREV I,KEY NS.Global assays of fibrinolysis［J］.Int J Lab Hematol,2017,39(5):441-447.
［18］SNODERLY HT,BOONE BA,BENNEWITZ MF.Neutrophil extracellular traps in breast cancer and beyond: current perspectives on NET stimuli,thrombosis and metastasis,and clinical utility for diagnosis and treatment［J］.Breast Cancer Res,2019,21(1):145.
［19］LIU Z, WANG J, LIAO F,et al.Tumor-educated platelets facilitate thrombus formation through migration［J］.Front Oncol,2022,24,12:857865.
［20］CARESTIA A,KAUFMAN T,RIVADENEYRA L,et al.Mediators and molecular pathways involved in the regulation of neutrophil extracellular trap formation mediated by activated platelets［J］.J Leukoc Biol,2016,99(1):153-162.
［21］NADIR Y,BRENNER B.Heparanase procoagulant activity in cancer progression［J］.Thromb Res,2016,140:S44-S48.
［22］AXELMAN E,HENIG I,CRISPEL Y,et al.Novel peptides that inhibit heparanase activation of the coagulation system［J］.Thromb Haemost,2014,112(3):466-477.
［23］ZHOU Y,TAO W,SHEN F,et al.The emerging role of neutrophil extracellular traps in arterial, venous and cancer-associated thrombosis［J］.Front Cardiovasc Med,2021,8:786387.
［24］ABDOL RN,ELASKALANI O,METHAROM P.Pancreatic cancer-induced neutrophil extracellular traps: a potential contributor to cancer-associated thrombosis［J］.Int J Mol Sci,2017,18(3):487.
［25］CEDERVALL J,OLSSON AK.Immunity gone astray - nets in cancer［J］.Trends Cancer,2016,2(11):633-634.
［26］FOLCO EJ,MAWSON TL,VROMMAN A,et al.Neutrophil extracellular traps induce endothelial cell activation and tissue factor production through interleukin-1alpha and cathepsin g［J］.Arterioscler Thromb Vasc Biol,2018,38(8):1901-1912.
［27］THALIN C,HISADA Y,LUNDSTROM S,et al.Neutrophil extracellular traps:villains and targets in arterial,venous,and cancer-associated thrombosis［J］.Arterioscler Thromb Vasc Biol,2019,39(9):1724-1738.
［28］THALIN C,DEMERS M,BLOMGREN B,et al.NETosis promotes cancer-associated arterial microthrombosis presenting as ischemic stroke with troponin elevation［J］.Thromb Res,2016,139:56-64.
［29］TREJO-BECERRIL C,PEREZ-CARDENAS E,GUTIERREZ-DIAZ B,et al.Antitumor effects of systemic dnase i and proteases in an in vivo model［J］.Integr Cancer Ther,2016,15(4):35-43.
［30］LEAL AC,MIZURINI DM,GOMES T,et al.Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancer-associated thrombosis［J］.Sci Rep,2017,7(1):6438.
［31］BURNOUF T,CHOU ML,GOUBRAN H,et al.An overview of the role of microparticles/microvesicles in blood components: are they clinically beneficial or harmful［J］.Transfus Apher Sci,2015,53(2):137-145.
［32］VAN NIEL G,D'ANGELO G,RAPOSO G.Shedding light on the cell biology of extracellular vesicles［J］.Nat Rev Mol Cell Biol,2018,19(4):213-228.
［33］DATE K,ETTELAIE C,MARAVEYAS A.Tissue factor-bearing microparticles and inflammation:a potential mechanism for the development of venous thromboembolism in cancer［J］.J Thromb Haemost,2017,15(12):2289-2299.
［34］LACROIX R,VALLIER L,BONIFAY A,et al.Microvesicles and cancer associated thrombosis［J］.Semin Thromb Hemost,2019,45(6):593-603.
［35］YAMANAKA Y,SAWAI Y,NOMURA S.Platelet-derived microparticles are an important biomarker in patients with cancer-associated thrombosis［J］.Int J Gen Med,2019,12:491-497.